Clinical trial
Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Neuroendocrine Tumors, Progressive Under Somatostatin Analogue Therapy
NCT02705313 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Neuroendocrine Tumors, Progressive Under Somatostatin Analogue Therapy
- Lead sponsor
- Advanced Accelerator Applications
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.